Stockreport

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene [Yahoo! Finance]

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data Demonstrated 100% CR/CRi Rate and Favorable Tolerability Profile -- -- Strengthened [Read more]